PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15772499-1 2005 We examined the effects of the 5-phosphodiesterase (5-PDE) inhibitor sildenafil on pulmonary arterial pressure and some oxygen transport and cardiopulmonary parameters in humans during exposure to hypobaric hypoxia at rest and after exercise. Sildenafil Citrate 69-79 aldehyde dehydrogenase 7 family member A1 Homo sapiens 54-57 18790048-8 2008 These data confirm PDE5 expression, activity, and targeted inhibition by sildenafil in cardiomyocytes, as well as the role of this PDE in cardiomyocyte hypertrophy modulation. Sildenafil Citrate 73-83 aldehyde dehydrogenase 7 family member A1 Homo sapiens 19-22 16100293-1 2005 Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile. Sildenafil Citrate 114-124 aldehyde dehydrogenase 7 family member A1 Homo sapiens 96-99 15633907-5 2004 International Guidelines has faced the problem of resuming sexual activity after a cardiac event and of the eventual suitability to the use of sildenafil or other selective inhibitor of cGMP-specific phosphodiesterase type 5 (5-PDE) for the therapy of ED in these patients. Sildenafil Citrate 143-153 aldehyde dehydrogenase 7 family member A1 Homo sapiens 228-231 10753463-1 2000 Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects. Sildenafil Citrate 93-103 aldehyde dehydrogenase 7 family member A1 Homo sapiens 26-29 12614192-3 2003 Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED. Sildenafil Citrate 107-117 aldehyde dehydrogenase 7 family member A1 Homo sapiens 166-169 12614192-3 2003 Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (Viagra, Pfizer) - the first approved selective PDE inhibitor for the treatment of ED. Sildenafil Citrate 119-125 aldehyde dehydrogenase 7 family member A1 Homo sapiens 166-169 12614192-4 2003 Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods. Sildenafil Citrate 0-10 aldehyde dehydrogenase 7 family member A1 Homo sapiens 28-31 12614192-4 2003 Sildenafil is inhibitory of PDE5 at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods. Sildenafil Citrate 0-10 aldehyde dehydrogenase 7 family member A1 Homo sapiens 81-85 12414329-7 2002 Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods. Sildenafil Citrate 0-10 aldehyde dehydrogenase 7 family member A1 Homo sapiens 47-50